TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36351926
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g of CaCO3
Study: 36351926
Drug: 0 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g of CaCO3
Study: 36351926
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g of CaCO3
Study: 36351926
Drug: 15 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g of CaCO3
Study: 36351926
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g of CaCO3
Study: 36351926
Drug: Genotype I
Normalized name: IOBENGUANE I 123
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genotype I and 5 g of CaCO3
Study: 33271534
Drug: Plasma magnesium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma magnesium concentrations in quartile 1 (<0.76 mmol/L)
Study: 33271534
Drug: Plasma magnesium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma magnesium concentrations in quartile 4 (≥0.89 mmol/L)
Study: 33271534
Drug: Plasma magnesium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma magnesium concentrations in quartile 3 (0.83 to <0.89 mmol/L)
Study: 32833845
Drug: Nonprogressive KCN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonprogressive KCN group (serum vitamin D levels: 12.77 ± 5.52 ng/mL)
Study: 32833845
Drug: Progressive KCN
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Progressive KCN group (serum vitamin D levels: 11.78 ± 4.32 ng/mL)
Study: 32833845
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (serum vitamin D levels: 17.40 ± 5.12 ng/mL)
Study: 36214945
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy for insomnia (exact dosage and duration not specified)
Study: 33143931
Drug: Goal-directed hemodynamic
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goal-directed hemodynamic therapy
Study: 33143931
Drug: Restrictive normovolemic
Normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive normovolemic therapy
Study: 32312645
Drug: Cemented femoral
Normalized name: Sus scrofa temporal lobe preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cemented femoral and tibial implants
Study: 32312645
Drug: Cemented tibial
Normalized name: Cacao seed oil, fermented
DrugBank: Cocoa butter (DB11086)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cemented tibial implant, uncemented femoral implant (hybrid group)
Study: 39018515
Drug: Tailored dose-dense
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored dose-dense chemotherapy
Study: 36052473
Drug: 3-components phytotherapic
Normalized name: Perftoran component perfluorodecalin
DrugBank: Perfluorodecalin (DB16292)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-components phytotherapic composed of Herniaria hirsuta and Peumus boldus plus water oral intake for 12 days/month over 3 months (Group A)
Study: 33851854
Drug: Follow-up/future treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Follow-up/future treatment costs
Study: 34507244
Drug: Initial combination
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial combination therapy (fluoropyrimidine, bevacizumab, irinotecan)
Study: 32093741
Drug: Lactocare (ZistTakhmir)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactocare (ZistTakhmir) capsules 500 mg every 12 hours for 14 days
Study: 32093741
Drug: Placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule containing only sterile maize starch, similar to synbiotic capsules for 14 days
Study: 32316886
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral treatment for insomnia (one group session of sleep hygiene education and four individual sessions of counseling)
Study: 32978842
Drug: Novel antibiotic-free
Normalized name: acid red 337 free acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel antibiotic-free film-forming silicone-based wound dressing
Study: 32978842
Drug: Topical triple
Normalized name: Triple Paste Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical triple antibiotic petrolatum-based ointment
Study: 33357512
Drug: Riluzole (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Riluzole (50 mg twice a day for 14 days before surgery and then for 28 days after surgery)
Study: 35321888
Drug: Completion surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Completion surgery followed by an additional five cycles of chemotherapy (control arm)
Study: 35321888
Drug: An additional
Normalized name: Aldex AN
DrugBank: Doxylamine (DB00366)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: An additional three cycles of neoadjuvant chemotherapy followed by completion surgery and then two additional cycles of chemotherapy (experimental arm)
Study: 32927371
Drug: Prolonged exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged exposure treatment
Study: 32927371
Drug: Non-exposure based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-exposure based treatment
Study: 33657450
Drug: SSRI treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSRI treatment (10mg escitalopram)
Study: 34510501
Drug: Average Treatment
Normalized name: immune globulin,alpha (IgA) average 46 mcg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Average Treatment Effect (ATE)
Study: 34227392
Drug: PCI with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCI with drug-eluting stents
Study: 35151504
Drug: Varenicline (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline (1 mg)
Study: 34278042
Drug: Fluoxetine 20
Normalized name: fluoxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 20 mg/day orally for 90 days
Study: 33601121
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Vitamin A (2000 IU/d) and Vitamin D (400 IU/d)
Study: 33601121
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (tuberculosis treatment only)
Study: 34755627
Drug: Maralixibat 380
Normalized name: Maralixibat
DrugBank: Maralixibat (DB16226)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maralixibat 380 μg/kg once per day for 18 weeks, followed by random assignment to continue maralixibat or receive placebo for 4 weeks.
Study: 34755627
Drug: Maralixibat continued
Normalized name: Maralixibat
DrugBank: Maralixibat (DB16226)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maralixibat continued treatment
Study: 34755627
Drug: Maralixibat continued
Normalized name: Maralixibat
DrugBank: Maralixibat (DB16226)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maralixibat continued treatment until week 204
Study: 33483613
Drug: IM 400
Normalized name: Bactrim 400mg-80mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM 400 mg
Study: 33483613
Drug: IM 600
Normalized name: Anthim 600 MG in 6 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM 600 mg
Study: 33483613
Drug: IM 400
Normalized name: Bactrim 400mg-80mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM 400 mg + cytarabine (AraC)
Study: 33483613
Drug: IM 400
Normalized name: Bactrim 400mg-80mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM 400 mg + pegylated interferon alpha2a (PegIFN‐α2a)
Study: 35472008
Drug: Esomeprazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole (40 mg twice daily)
Study: 34494323
Drug: 40 g
Normalized name: PEG-40 GLYCERYL STEARATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 g low-fat milk powder (placebo)
Study: 35468621
Drug: F16IL2 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: F16IL2 (10 × 10^6 to 20 × 10^6 IU IV; days 1, 8, 15, and 22 of each 28‐day cycle) + BI 836858 (10-40 mg IV, 2 days after each F16IL2 infusion)
Study: 35283262
Drug: Anti-inflammatory drug
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-inflammatory drug for heart failure
Study: 32347934
Drug: Olaparib 150
Normalized name: olaparib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olaparib 150 mg (3 days/week) with TMZ 75 mg/m2 daily for 42 days
Study: 36227220
Drug: Tailored nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored nutritional dietary rehabilitation plan including dietary supplements
Study: 34916320
Drug: Dose-intense regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-intense regimen of doxorubicin and cisplatin
Study: 32898170
Drug: Intramuscular stimulation
Normalized name: follicle stimulating hormone / luteinizing hormone Injection [Menopur]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular stimulation with a 12-week rehabilitation program (n = 25)
Study: 32898170
Drug: Sham intramuscular
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham intramuscular stimulation with a 12-week rehabilitation program (n = 19)
Study: 34499574
Drug: Recombinant rabies
Normalized name: rabies virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant rabies G protein vaccine
Study: 34499574
Drug: Reference vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference vaccine (five-dose WHO prequalified vaccine)
Study: 32744902
Drug: Secretion above
Normalized name: gonorrheal urethral secretion human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secretion above 25 mL (drainage longer than 24 hours)
Study: 32744902
Drug: Secretion below
Normalized name: gonorrheal urethral secretion human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secretion below 25 mL (drainage less than 24 hours)
Study: 34305584
Drug: Elaeagnus angustifolia
Normalized name: ELAEAGNUS ANGUSTIFOLIA WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elaeagnus angustifolia (15 g of the whole fruit powder)
Study: 34305584
Drug: Placebo (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (7.5 g isomalt + 7.5 g cornstarch)
Study: 34086524
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of kinesiotaping and stretching
Study: 35170783
Drug: Melatonin 10
Normalized name: melatonin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 10 mg administered every night for 24 weeks
Study: 35170783
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered every night for 24 weeks
Study: 34369908
Drug: Raltegravir 400
Normalized name: raltegravir 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltegravir 400 mg twice a day + Lamivudine 150 mg twice a day + Zidovudine 300 mg twice a day
Study: 34369908
Drug: Efavirenz 600
Normalized name: efavirenz 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efavirenz 600 mg four times a day + Lamivudine 150 mg twice a day + Zidovudine 300 mg twice a day
Study: 34598676
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg Trimetazidine (TMZ) 12 hours before surgery
Study: 32102086
Drug: Fezolinetant 15,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fezolinetant 15, 30, 60, 90 mg BID or 30, 60, 120 mg QD
Study: 34373282
Drug: Cabazitaxel chemotherapy
Normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cabazitaxel chemotherapy
Study: 34634757
Drug: Complex intervention
Normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complex intervention to reduce sedentary behaviour, details on dosage and duration not specified.
Study: 34106974
Drug: Problem-solving skills
Normalized name: Solv X
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problem-solving skills intervention delivered through 6 monthly sessions
Study: 33400348
Drug: Topiroxostat 40–160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiroxostat 40–160 mg/day
Study: 33400348
Drug: Febuxostat 10–60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Febuxostat 10–60 mg/day
Study: 33221788
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment during the same period)
Study: 34303445
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment conditions
Study: 34399847
Drug: CBT‐VR (Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBT‐VR (Cognitive Behavioural Therapy and Vestibular Rehabilitation)
Study: 36179772
Drug: Good adherence
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Good adherence to oral anticoagulants (OACs) defined as proportion of days covered (PDC) >80%
Study: 33865507
Drug: Ravidasvir (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ravidasvir (200 mg once daily) plus Sofosbuvir (400 mg once daily) for 12 weeks (no cirrhosis) or 24 weeks (with cirrhosis)
Study: 35466343
Drug: Control condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control condition (transducer on intravenous pole)
Study: 35507912
Drug: Booster vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster vaccination with 5, 10, and 20 μg hepatitis B vaccines or 5 μg hepatitis A and B (HAB) combination vaccine with a 0-1-6-month schedule (schedule 2 group)
Study: 39514041
Drug: Tezepelumab 210
Normalized name: TEZEPELUMAB 210 mg in 1.9 mL SUBCUTANEOUS INJECTION, SOLUTION [TEZSPIRE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tezepelumab 210 mg subcutaneously every 4 weeks for 52 weeks
Study: 38802635
Drug: Tezepelumab 210
Normalized name: TEZEPELUMAB 210 mg in 1.9 mL SUBCUTANEOUS INJECTION, SOLUTION [TEZSPIRE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tezepelumab 210 mg
Study: 32314514
Drug: Aloe extract
Normalized name: aloe extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aloe extract treatment for 4 weeks
Study: 32314514
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (inulin) for 4 weeks
Study: 32314514
Drug: Aloe treatment
Normalized name: Aloe
DrugBank: Aloe ferox leaf (DB14257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aloe treatment responders (n = 33, 39%)
Study: 32314514
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment responders (n = 34, 45%)
Study: 35821950
Drug: Preoperative educational
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative educational video and postoperative acceptance and commitment therapy (ACT)
Study: 32334553
Drug: Self-administered drug
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered drug intake supported by a family member
Study: 33356422
Drug: Irinotecan and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan and cetuximab with vemurafenib (960 mg PO twice daily)
Study: 33243018
Drug: Quxie capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quxie capsule (QX) treatment
Study: 34470831
Drug: Iron sucrose
Normalized name: Iron Sucrose
DrugBank: Iron sucrose (DB09146)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron sucrose (100 mg biweekly, total 2 g over 40 weeks)
Study: 34470831
Drug: Ferric carboxymaltose
Normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ferric carboxymaltose (500 mg every 10 weeks, total 2 g over 40 weeks)
Study: 34470831
Drug: Erythropoiesis-stimulating agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoiesis-stimulating agent use
Study: 34965603
Drug: Absorbable nasal
Normalized name: COLLAGEN HEMOSTAT,ABSORBABLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Absorbable nasal implant
Study: 32318809
Drug: Fedratinib 500
Normalized name: FEDRATINIB
DrugBank: Fedratinib (DB12500)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fedratinib 500 mg single dose
Study: 36227659
Drug: mPEG-HA-Pt treatment
Normalized name: MPEG 6000 acetyl lysine
Approvals — FDA: no, EMA: no, PMDA: no
Description: mPEG-HA-Pt treatment
Study: 36227659
Drug: Traditional chemotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional chemotherapy (control)
Study: 35114286
Drug: Instant coffee
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Instant coffee with 3 mg/kg caffeine
Study: 35114286
Drug: Instant coffee
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Instant coffee with 6 mg/kg caffeine
Study: 33747510
Drug: Ligelizumab (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ligelizumab (240 mg q2w)
Study: 35727573
Drug: Multispecies probiotic
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multispecies probiotic (10 billion CFUs daily during antibiotic treatment and for 7 days after)
Study: 33125674
Drug: Globalagliatin (high-dose)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Globalagliatin (high-dose)
Study: 32124728
Drug: 1 μg/serotype/dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 μg/serotype/dose adjuvanted with aluminum
Study: 32124728
Drug: 1 μg/serotype/dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 μg/serotype/dose adjuvanted with AS01E
Study: 32124728
Drug: 1 μg/serotype/dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 μg/serotype/dose adjuvanted with AS03B
Study: 32124728
Drug: 4 μg/serotype/dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 μg/serotype/dose adjuvanted with aluminum
Study: 33664127
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (paclitaxel 175 mg/m2 plus cisplatin 50 mg/m2 or carboplatin AUC=6 every 3 weeks for six cycles)
Study: 33664127
Drug: Adjuvant concurrent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant concurrent chemoradiotherapy (whole pelvis irradiation 50.4 Gy and cisplatin 40 mg/m2/week)
Study: 34749319
Drug: Low-intensity magnetic
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity magnetic laser therapy (LLLT)
Study: 35011083
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg of WHS
Study: 34914845
Drug: Survivorship Sleep
Approvals — FDA: no, EMA: no, PMDA: no
Description: Survivorship Sleep Program (SSP) - 4 weekly sessions
Study: 32873406
Drug: Hong Kong
Normalized name: Influenza A virus Hong Kong Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hong Kong strain vaccine
Study: 32873406
Drug: Saitama strain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saitama strain vaccine
Study: 32873406
Drug: Both vaccines
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both vaccines against A/Osaka/188/2017
Study: 34743666
Drug: Switch to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switch to dolutegravir 50 mg once daily for 120 days
Study: 34743666
Drug: Remain on
Normalized name: Remain Gold
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remain on raltegravir 400 mg twice daily
Study: 32998932
Drug: Single postoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single postoperative dose of zoledronic acid
Study: 35678882
Drug: Oral sucrosomial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sucrosomial iron supplementation (30 mg daily for 12 weeks)
Study: 35678882
Drug: No supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: No supplementation to ESA treatment (Control group)
Study: 32179149
Drug: Colistin loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colistin loading dose (LD group) of 4 mg of colistin base activity (CBA)/kg/dose
Study: 32179149
Drug: Standard initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard initial dose (NLD group) of 2.5 mg (12‐h interval) or 1.7 mg (8‐h interval) of CBA/kg/dose
Study: 35318290
Drug: Immediate implants
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate implants (Group I)
Study: 35318290
Drug: Delayed implants
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed implants (Group II)
Study: 34523115
Drug: P2Y12 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: P2Y12 inhibitor monotherapy (mostly clopidogrel) following 12 months of DAPT
Study: 35357957
Drug: Cognitive Processing
Normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Processing Group Therapies
Study: 33801295
Drug: EMG-triggered robotic
Normalized name: PROBIOTIC
DrugBank: Bifidobacterium longum (DB19248)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMG-triggered robotic rehabilitation device treatment
Study: 35863995
Drug: Quadratus Lumborum
Normalized name: Pisum quadratum whole
DrugBank: Pisum sativum whole (DB15545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadratus Lumborum Block (QLB) with continuous infusion of bupivacaine 0.1% at 7 mL/h for 24 hours
Study: 35863995
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Group M) received intravenous morphine patient controlled analgesia for 24 hours
Study: 32649388
Drug: Daily disposable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily disposable contact lens (DDCL) fitting (delefilcon A)
Study: 33199752
Drug: PM-EE 600
Normalized name: norgestimate
DrugBank: Norgestimate (DB00957)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PM-EE 600 mg/day
Study: 32872000
Drug: Goreisan (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goreisan (7.5 g/d for 12 weeks)
Study: 32872000
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (no Kampo medicine)
Study: 33642357
Drug: Drotaverine (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drotaverine (80 mg three times a day, 1 hour before meals)
Study: 33642357
Drug: Mebeverine (135
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mebeverine (135 mg three times a day, 1 hour before meals)